Document Detail

Evaluation of Cuprimine and Syprine for decorporation of (60)Co and (210)Po.
MedLine Citation:
PMID:  20147789     Owner:  NLM     Status:  MEDLINE    
The acknowledged risk of deliberate release of radionuclides into local environments by terrorist activities has prompted a drive to improve novel materials and methods for removing internally deposited radionuclides. These decorporation treatments will also benefit workers in the nuclear industry, should an exposure occur. Cuprimine and Syprine are oral therapeutics based on the active ingredients D-penicillamine and N,N'-bis-(2-aminoethyl)-1,2-ethanediamine dihydrochloride, respectively. These therapeutic drugs have been used for several decades to treat Wilson's disease, a genetic defect leading to copper overload, by chelation and accelerated excretion of internally deposited copper. Studies were undertaken to evaluate these FDA-approved drugs for the in vivo decorporation of radioactive cobalt (Co) and polonium (Po) using male Wistar-Han rats. In these studies, Co or Po was administered to animals by IV injection, followed by oral gavage doses of either Cuprimine or Syprine. Control animals received the radionuclide alone. For Co studies, animals received a single dose of Cuprimine or Syprine, while for Po studies animals were repeatedly dosed at 24-h intervals for a total of 5 doses. Results show that Syprine significantly increased urinary elimination and skeletal concentrations of Co compared to controls. While Cuprimine had little effect on total excretion of Co, the skeletal, kidney, liver, muscle, and stomach tissues had significantly lower radioactivity compared to control animals. The low overall excretion of Po made it difficult to reliably measure urinary or fecal radioactivity and draw a definitive conclusion on the effect of Cuprimine or Syprine treatment on excretion. However, Cuprimine treatment was effective at reducing spleen levels of Po compared to controls. Similarly, Syprine treatment produced statistically significant reductions of Po in the spleen and skeletal tissues compared to control animals. Based on these promising findings, further studies to evaluate the dose-response pharmacokinetic profiles for decorporation are warranted.
Tatiana G Levitskaia; Jeffrey A Creim; Terry L Curry; Teresa Luders; James E Morris; Angela D Woodstock; Barry Levinson; Karla D Thrall
Related Documents :
16638679 - Pharmacokinetic, tissue distribution, and excretion of puerarin and puerarin-phospholip...
18087819 - Effect of probenecid on the biliary excretion of belotecan.
8237059 - Biological fate of sulphur mustard in rat: toxicokinetics and disposition.
6546919 - The fate of drotaverine-acephyllinate in rat and man. ii. human pharmacokinetics of dro...
3805709 - Biliary excretion and organ distribution of 14c radioactivity after 14c-2-ethylhexyl ac...
555469 - Metabolism and distribution of 2,4,5-trichlorophenoxyacetic acid (2,4,5-t) in pregnant ...
3165539 - Pgf2 alpha-induced milk ejection in ewes having cyclic or pregnant corpora lutea.
21560029 - Solar uv exposure of children in a summer school in valencia, spain.
8849179 - Comparing the efficacy of pefloxacin and ciprofloxacin in the treatment of acute uncomp...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Health physics     Volume:  98     ISSN:  1538-5159     ISO Abbreviation:  Health Phys     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-11     Completed Date:  2010-03-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985093R     Medline TA:  Health Phys     Country:  United States    
Other Details:
Languages:  eng     Pagination:  471-9     Citation Subset:  IM    
Battelle, Pacific Northwest Division, Richland, WA 99352, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chelating Agents / administration & dosage,  chemistry,  pharmacology
Cobalt Radioisotopes / chemistry,  isolation & purification*,  pharmacokinetics
Penicillamine / administration & dosage,  chemistry*,  pharmacology*
Polonium / chemistry*,  isolation & purification*,  pharmacokinetics
Rats, Wistar
Tissue Distribution
Triethylenetetramine / administration & dosage,  chemistry*,  pharmacology*
Reg. No./Substance:
0/Chelating Agents; 0/Cobalt Radioisotopes; 112-24-3/Triethylenetetramine; 52-67-5/Penicillamine; 7440-08-6/Polonium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Next Document:  Characterization of the world's first nuclear explosion, the trinity test, as a source of public rad...